LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

Abstract

Premenopausal breast cancer patients have an increased long-term risk for fatal disease, and endocrine therapy benefit including ovarian suppression is unexplored. Here for the first time, we assessed the 20-year benefit of goserelin and tamoxifen stratified by the molecular 70-gene signature risk prediction in premenopausal women in a randomized trial.